ARK持倉追蹤12.31 | 連續6次減持特斯拉
以下數據爲Cathie Wood個人/所在機構的過往操作,其交易背後之投資邏輯並不明確,不代表投資建議,跟蹤操作注意風險。
【12.31持倉變化小結】
①ARK系列主動型ETF當日共操作11筆,其中買入9只股票,賣出2只股票。
②加倉ZOOM,屬於當月第五次加倉。Zoom第三季度營收7.772億美元,淨利同比激增89倍。Zoom第三季度業績以及第四季度和2021財年業績展望均超出華爾街分析師預期。
③當日賣出特斯拉,12月共6個交易日賣出特斯拉,並有持續賣出的趨勢。
④連續4個交易日加倉再生元製藥公司,12月一共加倉8次。再生元製藥公司聯合使用casirivimab和imdevimab的新冠抗體雞尾酒療法已經獲得美國食品和藥物管理局(FDA)的緊急使用授權。
⑤連續8個交易日加倉羅氏控股,12月一共加倉19次。羅氏集團始創於1896年,羅氏總部位於瑞士巴塞爾,在製藥和診斷領域是世界領先的。

【ARK系列ETF介紹】
①ARKK:以顛覆性創新產業爲主要投資標的
ARKK專門投資革命性創新的公司,在5個美股ETF中,ARKK投資的公司類型最多元化,包括基因科技、全自動化、物聯網及金融科技相關的公司,可以說是其餘4個ETF的合體。
②ARKQ:以自動科技自動機器人技術爲主要投資標的
ARKQ投資的公司專注於機器人自動化相關的公司,當中投資自動駕駛的公司佔比最多,其次爲自動化機器人、3D打印、儲能技術、太空探索等的相關公司。
③ARKF :以金融科技創新爲主要投資標的
ARKF主力投資金融科技相關公司,其中包括交易平臺、區塊鏈、衆籌平臺等等相關公司。
④ ARKW:以"下一代網絡"爲主要投資標的
ARKW專門投資"下一代網絡"的公司,當中佔比最多的公司爲雲計算、其次爲網絡安全、電子商務、大數據、人工智能等相關公司。
⑤ ARKG:以生物基因科技創新爲主要投資標的
ARKG這隻ETF主要專注於基因革命領域,包括基因編輯技術CRISPR、基因診斷治療、靶向治療、生物信息。
【Usmart目前支持部分ETF進行10倍槓桿日內交易,港股交易ETF無需繳納印花稅,對於日內短線交易而言,可降低交易成本
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.